by Geling Li, Emily Waite, and Julie Wolfson

Slides:

Advertisements

Similar presentations

The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase–dependent cleavage of calreticulin in AML patients by Sarah Mans, Yara Banz,

Advertisements

How I treat prolymphocytic leukemia

Kazunori Kanehira, Douglas L. Riegert-Johnson, Dong Chen, Lawrence E

Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient Kuan-Nien Chou, Yu-chieh Lin, Ming-Ying.

Copyright © 2014 American Medical Association. All rights reserved.

Biological aspects of Epstein–Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies Hirokazu Kanegane, Keiko.

Increased apoptosis of peripheral blood T cells following allogeneic hematopoietic cell transplantation by Ming-Tseh Lin, Li-Hui Tseng, Haydar Frangoul,

by Manuella L. Gomes Ochtrop, Sigune Goldacker, Annette M

Bone Marrow Graft-versus-Host Disease: Evaluation of Its Clinical Impact on Disrupted Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation

by Rahul Matnani, and Karthik A. Ganapathi

How I treat LGL leukemia

Immunologic effects of F16-IL2 therapy.

by Udomsak Bunworasate, Hilal Arnouk, Hans Minderman, Kieran L

Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease by Marijke R. Canninga-van Dijk, Hanneke.

by Thomas S. Uldrick, and Richard F. Little

Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection by Koen Van Besien, Sonali Smith,

Morphological analyses of peripheral blood and bone marrow cells isolated from leukemic mice. Morphological analyses of peripheral blood and bone marrow.

Leukemia initiated by PMLRARα: the PML domain plays a critical role while retinoic acid–mediated transactivation is dispensable by Scott C. Kogan, Suk-hyun.

by Qin Huang Blood Volume 122(1):6-6 July 4, 2013

SOX11 holds mantle cell lymphoma’s key to home

Fusion genes in cord blood

Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation by George E. Georges, Rainer Storb, Jennifer.

Resolution of osteosclerosis after alloHCT in systemic mastocytosis

Full hematopoietic engraftment after allogeneic bone marrow transplantation without cytoreduction in a child with severe combined immunodeficiency by Ronald.

Effect of a Recombinant Dimeric Tumor Necrosis Factor Receptor on Inflammatory Responses to Intravenous Endotoxin in Normal Humans by Tom van der Poll,

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate by E.L.

Chronic lymphocytic leukemia and cryoglobulinemic glomerulonephritis

by Hyung-Gyoon Kim, Kyoko Kojima, C. Scott Swindle, Claudiu V

Kazunori Kanehira, Douglas L. Riegert-Johnson, Dong Chen, Lawrence E

BCL-6 Protein Expression in Human Peripheral T-Cell Neoplasms Is Restricted to CD30+ Anaplastic Large-Cell Lymphomas by Antonino Carbone, Annunziata Gloghini,

Evidence for Circulating Bone Marrow-Derived Endothelial Cells

Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ T-cell restoration.

HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8–positive plasmablastic lymphoma by Nicolas Dupin, Tim L.

Complete remission through blast cell differentiation inPLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies by Maria C. Petti,

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models by Paola Rivera-Munoz, Anouchka P. Laurent,

Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation by Wenbin Xiao, Mariko Yabe, Michael.

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

VAY-736 combines effectively with ibrutinib in vivo.

by Dana T. Lounder, Qiong Bin, Cristina de Min, and Michael B. Jordan

Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines by Yanyan Zhang, Liang He, Dorothée.

Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients by Erica B. Esrick, John P. Manis,

BCR-ABL1 gene rearrangement as a subclonal change in ETV6-RUNX1–positive B-cell acute lymphoblastic leukemia by Karen A. Dun, Rob Vanhaeften, Tracey J.

Interleukin-2–inducible T-cell kinase inhibitors modify functional polarization of human peripheral T-cell lymphoma cells by Sami Mamand, Matthew Carr,

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.

by Gabriela M. Webb, Shengbin Li, Gwantwa Mwakalundwa, Joy M

Clonotypic heterogeneity in cutaneous T-cell lymphoma (mycosis fungoides) revealed by comprehensive whole-exome sequencing by Aishwarya Iyer, Dylan Hennessey,

NUP98-HBO1–fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis by Yoshihiro Hayashi, Yuka Harada, Yuki.

Pure Erythroid Leukemia Presenting in a HIV-Positive Patient

Figure MRI brain comparison prior and after treatment and brain biopsy findings MRI brain comparison prior and after treatment and brain biopsy findings.

Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura by Liang Zheng, Yingying.

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

Figure 2 Brain biopsy of 2 patients with anti-MOG encephalitis initially misdiagnosed with small vessel CNS vasculitis Brain biopsy of 2 patients with.

A case of lenalidomide-dependent myelodysplastic syndrome

PD-L1 and tumor-associated macrophages in de novo DLBCL

by Matthew S. Painschab, Kate D

Acute Megakaryocytic Leukemia

Resistance mechanism for ibrutinib in marginal zone lymphoma

by Catherine Lai, Vishal Ranpura, Colin Wu, Matthew J. Olnes, Ankur R

Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.

Biology and treatment of Richter syndrome

Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations by Ami B. Patel, Erin M. Pettijohn,

Histopathologic examination of a specimen obtained from left lentiform nucleus by stereotactic biopsy. Histopathologic examination of a specimen obtained.

Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain and ×10 growth). Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain.

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI by Naranie Shanmuganathan, Susan.

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity by Benjamin L. Lampson, Siddha.

Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.

Myeloid neoplasms with eosinophilia

Metastatic adenocarcinoma.

Presentation transcript:

by Geling Li, Emily Waite, and Julie Wolfson T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib)‏ by Geling Li, Emily Waite, and Julie Wolfson BloodAdv Volume 1(27):2724-2728 December 26, 2017 © 2017 by The American Society of Hematology

T-PLL involving lymph node, peripheral blood, pleural fluid, and bone marrow. T-PLL involving lymph node, peripheral blood, pleural fluid, and bone marrow. Diffuse infiltrate of T-PLL in the cervical lymph node by morphology (A [original magnification ×400, hematoxylin and eosin stain]) and CD8 immunostain (B [original magnification ×400]). T-PLL in the peripheral blood (C [original magnification ×1000, Wright-Giemsa stain]) and pleural fluid (D [original magnification ×1000, Wright-Giemsa stain]). Persistent and diffuse involvement of bone marrow by T-PLL status post–4-week treatment with alemtuzumab by morphology (E [original magnification ×40, hematoxylin and eosin stain]) and CD8 immunostain (F [original magnification ×40]). Addition of JAK inhibitor tofacitinib to alemtuzumab markedly decreased the leukemic cells in a repeat bone marrow biopsy by morphology (G [original magnification ×40, hematoxylin and eosin stain]) and CD8 immunostain (H [original magnification ×40]). Geling Li et al. Blood Adv 2017;1:2724-2728 © 2017 by The American Society of Hematology

Trends of peripheral counts through treatment. Trends of peripheral counts through treatment. Absolute lymphocyte count (A), hemoglobin (B), and platelet count (C) in the peripheral blood before and after treatment are shown in the y-axis; x-axis represents timeline in days. The time points at which alemtuzumab and tofacitinib were added are indicated by arrows. The time points at which the patient received red blood cell transfusions for panel B and platelet transfusions for panel C are indicated by blue arrows. Hb, hemoglobin; PB, peripheral blood; Plt, platelet. Geling Li et al. Blood Adv 2017;1:2724-2728 © 2017 by The American Society of Hematology